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Purpose: Sevelamer hydrochloride/carbonate (SH/C)
and lanthanum carbonate (LC) are noncalcium-based
phosphate binders used for the management of hyper-
phosphatemia in patients with end-stage renal disease
(ESRD). The objectives of this study were to examine
the dose-relativity, tablet burden, and cost difference of
bidirectional conversion between SH/C and LC mono-
therapy in a large cohort of real-world patients with
ESRD.
Methods: This retrospective cohort study included
three 30-day preconversion periods (days 90 to 61,
60 to 31, and 30 to 1) followed by three 30-
day postconversion periods (days 1 to 30, 31 to 60,
and 61 to 90); day 0 was the index date of conversion.
The full analysis population (FAP) comprised two
cohorts: SH/C to LC (S–L) converters and LC to SH/C
(L–S) converters. The SH/C:LC dose-relativity ratio
was assessed in the dose-relativity subset, deﬁned as
patients whose serum phosphate levels fell within a
caliper range of 0.5 mg/dL in the ﬁnal preconversion
(days 30 to 1) and postconversion (days 61 to 90)
periods. Tablet burden and phosphate binder costs
were assessed in the FAP. Phosphate binder costs were
based on average wholesale prices.
Findings: The FAP contained a total of 303
patients, comprising the S–L (128 patients) and L–S
(175 patients) converter cohorts. The dose-relativity
subset contained 159 patients, 72 from the S–L cohort
and 87 from the L–S cohort. The overall mean SH/C:
LC dose-relativity ratio was 2.27 (95% CI, 2.04 to
2.52). In SH/C dose strata 4800 to 2400, 42400 to
4800, 44800 to 7200, and 47200 mg/d, overall
mean dose-relativity ratios were 0.79 (95% CI, 0.57
to 1.10), 1.45 (95% CI, 1.20 to 1.75), 2.05 (95% CI,
1.75 to 2.39), and 3.24 (95% CI, 2.89 to 3.66),October 2014respectively. The overall mean tablet burden was
6.6 tablets per day lower with LC monotherapy than
with SH/C monotherapy (95% CI, 7.1 to 6.0;
P o 0.0001). The overall mean binder cost/patient
per month was $1080.40 for SH/C compared with
$1006.20 for LC, corresponding to a mean binder
cost saving for LC of $74.20/patient per month (95%
CI, 141.80 to 6.63; P ¼ 0.032). SH/C47800 mg/d
was the inﬂection point at which conversion to LC
resulted in mean cost savings. Patients requiring SH/C
47800 mg/d comprised 50% of the FAP.
Implications: Converting patients with ESRD and
hyperphosphatemia from SH/C to LC monotherapy
offers potential drug cost savings and a signiﬁcant
reduction in the daily tablet burden, without compro-
mising the effective management of serum phosphate
levels. (Clin Ther. 2014;36:1431–1442) & 2014 The
Authors. Published by Elsevier HS Journals, Inc.
Key words: cost-effectiveness, dose-relativity, end-
stage renal disease, hyperphosphatemia, lanthanum
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In patients with end-stage renal disease (ESRD),
dysregulated phosphate excretion results in elevated
serum phosphate levels (hyperphosphatemia).1,2 Epi-
demiologic studies have shown that ESRD patients
with hyperphosphatemia have signiﬁcantly higher1431
Clinical Therapeuticsrates of morbidity and mortality than those who have
controlled serum phosphate levels.3–5 The clinical
management of hyperphosphatemia requires oral
phosphate binder therapy, in conjunction with dialysis
and dietary phosphate restriction.6,7 The two main
types of phosphate binders, calcium-based and non-
calcium-based, have a similar efﬁcacy in controlling
serum phosphate levels.8 However, calcium-based
binder use is associated with hypercalcemia,8
vascular calciﬁcation,9–11 and adynamic bone dis-
ease.12,13 In an updated meta-analysis, Jamal et al14
reported a 22% reduction in all-cause mortality in
patients receiving noncalcium-based phosphate bind-
ers compared with calcium-based binders. These ﬁnd-
ings are reﬂected in phosphate binder usage data,
which indicate that noncalcium-based binders are now
more widely used than calcium-based binders.15,16
The most commonly prescribed noncalcium-based
binders in clinical practise are sevelamer hydrochlor-
ide/carbonate and lanthanum carbonate.16 Sevelamer
hydrochloride/carbonate, the two forms of sevelamer,
are equivalent in terms of both efﬁcacy17–19 and cost
per 800-mg tablet.20 Sevelamer hydrochloride/
carbonate and lanthanum carbonate are expected to
be incorporated in the US Medicare bundled
reimbursement scheme for ESRD,21 which is to be
implemented in 2024.22 In light of these emerging
changes to the US ESRD payment system, the dose-
relativity (deﬁned as the ratio of mean daily doses
required to achieve similar phosphate levels), tablet
burden, and comparative costs of sevelamer
hydrochloride/carbonate and lanthanum carbonate
are important factors that need to be considered by
nephrologists in the management of ESRD services.
The objectives of the present analysis were to
examine the dose-relativity, tablet burden, and com-
parative drug costs in a large cohort of real-world
patients with ESRD who converted in either direction
between sevelamer hydrochloride/carbonate mono-
therapy and lanthanum carbonate monotherapy.
PATIENTS AND METHODS
Patients
Adult patients (aged Z18 years) with ESRD who
received in-center maintenance hemodialysis at a
single large dialysis organization (LDO) in the United
States and prescription pharmacy beneﬁts through the
pharmacy beneﬁts management program of the LDO
were included in the study. Patients who received1432calcium acetate/carbonate as a phosphate binder were
excluded from the study, as were patients receiving
aluminium-based or magnesium-based phosphate
binders.
Study Design
This was a retrospective cohort study of patients
with ESRD who converted in either direction between
sevelamer hydrochloride/carbonate monotherapy and
lanthanum carbonate monotherapy between October
30, 2006, and July 9, 2013. Sevelamer hydrochloride/
carbonate use was restricted to tablet formulations;
patients who received sevelamer hydrochloride/carbon-
ate powder were excluded from the study. In accord-
ance with the bidirectional study design, the full
analysis population (FAP) comprised two monotherapy
cohorts: sevelamer hydrochloride/carbonate to lantha-
num carbonate (S–L) converters and lanthanum carbo-
nate to sevelamer hydrochloride/carbonate (L–S)
converters. The study included three 30-day precon-
version periods (days 90 to 61, 60 to 31, and
30 to 1) followed by three 30-day postconversion
periods (days 1 to 30, 31 to 60, and 61 to 90); day 0
was the index date of conversion (Figure 1). The study
was restricted to patients who had similar degrees of
phosphate control in the last month of the preconversion
(days 30 to 1) and postconversion (days 61 to 90)
periods, deﬁned as both serum phosphate values falling
within the same stratum: o3.5, 3.5 to 5.5, 5.6 to 6.5,
and 46.5 mg/dL. During the preconversion period,
there had to be a minimum of 81 days (90%)
coverage of the preconversion binder with no
postconversion binder coverage; equally, during the
postconversion treatment period, there had to be a
minimum of 90% coverage of the postconversion
binder with no preconversion binder coverage. The
requirement for 90% coverage was to ensure a
consistently high level of drug usage and comparable
levels of adherence during the preconversion and
postconversion periods.
Retrospective Data Capture
Patient-level demographic characteristics, comorbidity-
related characteristics, and laboratory measures were
abstracted from the centralized data warehouse of the
LDO. Serum calcium and serum phosphate levels and
the urea reduction ratio were determined for each 30-
day study period; serum parathyroid hormone (PTH)
levels were determined quarterly (days 90 to 1 andVolume 36 Number 10
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Figure 1. Study design. SH/C ¼ sevelamer hydrochloride/carbonate; LC ¼ lanthanum carbonate; S–L ¼ SH/C
to LC conversion; L–S ¼ LC to SH/C conversion.
M.S. Keith et al.days 1 to 90), corresponding to the frequency with
which these analytes were measured according to the
clinical protocol. Assessment of the use of oral
medication was based on prescription ﬁll data by
using the pharmacy database of the LDO. Lanthanum
carbonate, sevelamer hydrochloride/carbonate, cina-
calcet, and activated vitamin D doses were determined
for each 30-day study period.
Data Analyses
The sevelamer hydrochloride/carbonate:lanthanum
carbonate dose-relativity ratio was deﬁned as the ratio
of mean daily doses required to achieve similar serum
phosphate levels. Dose-relativity estimates were as-
sessed in the dose-relativity subset, deﬁned as patients
whose serum phosphate levels fell within a caliper
range of 0.5 mg/dL in the ﬁnal preconversion (days
30 to 1) and postconversion (days 61 to 90)
periods. Tablet burden and phosphate binder costs
were assessed in the FAP. Tablet burden was deﬁned
as the prescribed daily number of phosphate binder
tablets per patient. Phosphate binder costs were
calculated from mean daily doses, based on September
2013 Red Book average wholesale prices.20 Tablet
burden difference and cost difference were calculated
as the lanthanum carbonate value minus the sevelamer
hydrochloride/carbonate value. For S–L converters,
this amount was the total daily value for days 61 to 90
(lanthanum carbonate value) minus the total daily
value for days 30 to 1 (sevelamer hydrochloride/
carbonate value). For L–S converters, the cost
difference was calculated as the total daily value for
days 30 to 1 (lanthanum carbonate value) minusOctober 2014the total daily value for days 61 to 90 (sevelamer
hydrochloride/carbonate value). Additional analyses
by sevelamer hydrochloride/carbonate daily require-
ment strata were also conducted; for these analyses,
the sevelamer hydrochloride/carbonate requirement
was deﬁned as the daily dose for days 30 to 1
(for S–L converters) and days 61 to 90 (for L–S
converters).
Statistical Analyses
Log transformations were applied to account for
non-Gaussian distributions of dose and dose-relativity
ratio data. Transformed means (with 95% CIs) were
then back-transformed to the original scale. Statistical
comparisons of preconversion and postconversion
values (days 30 to 1 vs days 61 to 90) were
conducted by using the paired t test.
RESULTS
Patients
The FAP contained 303 patients, comprising the
S–L converter (128 patients) and L–S converter (175
patients) cohorts. The two cohorts were broadly
similar in terms of demographic and comorbidity-
related characteristics, with the exception that the
mean dialysis duration in the L–S converters was
12 months longer than that for the S–L converters
(Table I).
Serum Parameters, Medication Use, and
Phosphate Binder Doses
Laboratory assessments, medication use, and
phosphate binder doses across each 30-day study1433
Table I. Patient demographic characteristics and
comorbidities.
Characteristic
S–L
Converters
(n ¼ 128)
L–S
Converters
(n ¼ 175)
Age, mean (SD), y 48.7 (13.4) 49.2 (14.6)
Female 47 (36.7%) 70 (40.0%)
Race
White 27 (21.1%) 50 (28.6%)
Black 43 (33.6%) 66 (37.7%)
Hispanic 47 (36.7%) 45 (25.7%)
Other 11 (8.6%) 14 (8.0%)
Etiology of ESRD
Hypertension 38 (29.7%) 59 (33.7%)
Diabetes 55 (43.0%) 52 (29.7%)
Other 33 (25.8%) 59 (33.7%)
Missing 2 (1.6%) 5 (2.9%)
Dialysis duration, mean
(SD), mo
41.5 (38.6) 53.7 (47.6)
Diabetes 74 (57.8%) 104 (59.4%)
Heart failure 10 (7.8%) 23 (13.1%)
Coronary artery disease 4 (3.1%) 12 (6.9%)
Charlson comorbidity
index, mean (SD)
4.2 (1.9) 4.3 (1.7)
S–L ¼ sevelamer hydrochloride/carbonate to lanthanum
carbonate; L–S ¼ lanthanum carbonate to sevelamer
hydrochloride/carbonate; ESRD ¼ end-stage renal
disease.
Clinical Therapeuticsperiod are reported for S–L and L–S converters in
Table II. Mean (SD) serum phosphate levels in the
S–L cohort fell from 6.4 (1.8) to 5.9 (1.6) mg/dL in
the 30-day period immediately after conversion to
lanthanum carbonate but subsequently rebounded to
6.4 (1.9) mg/dL in the ﬁnal 30-day period of
lanthanum carbonate monotherapy. A similar tem-
poral pattern was observed in the L–S cohort: mean
serum phosphate levels fell from 6.5 (1.9) to
6.3 (1.8) mg/dL immediately after conversion to
sevelamer hydrochloride/carbonate and then in-
creased to 6.4 (1.8) mg/dL. The mean seve-
lamer hydrochloride/carbonate dose ranged from
8217 (3674) to 8294 (3618) mg/d in the S–L cohort
and from 8569 (3961) to 8645 (3947) mg/d in the L–
S cohort. The mean lanthanum carbonate dose
ranged from 3817 (2215) to 3821 (2192) mg/d in
the L–S cohort and from 3362 (1283) to
3443 (1396) mg/d in the S–L cohort.1434Mean serum calcium levels were consistent across
all six time periods for both S–L (9.1 [0.6] to 9.2 [0.6]
mg/dL) and L–S (9.1 [0.7] to 9.2 [0.7] mg/dL)
converters. Median (25th percentile, 75th percentile)
serum PTH levels in the S–L cohort increased from
363.3 (244.3, 518.0) pg/mL in the preconversion
period to 386.7 (275.7, 601.5) pg/mL in the post-
conversion period. In the L–S cohort, median (25th
percentile, 75th percentile) serum PTH levels were
396.8 (271.3, 587.0) and 384.5 (265.0, 624.2) pg/mL,
respectively. Vitamin D usage ranged from 86%
to 93% for S–L converters and from 86% to 88%
for L–S converters. The mean urea reduction ratio was
consistently in the range of 72 to 73 for both S–L and
L–S converters, indicating that patients were ad-
equately dialyzed during the study.Sevelamer Hydrochloride/Carbonate:Lanthanum
Carbonate Dose-Relativity Ratio
Dose-relativity was assessed in the dose-relativity
subset, comprising 72 patients from the S–L cohort
and 87 patients from the L–S cohort. Mean dose-
relativity ratios for the S–L and L–S cohorts and the
pooled cohort sample were 2.43 (95% CI, 2.11 to
2.79), 2.14 (95% CI, 1.84 to 2.49), and 2.27 (95%
CI, 2.04 to 2.52), respectively (Table III). Analysis of
dose-relativity according to sevelamer hydrochloride/
carbonate requirement showed that the dose-relativity
ratio increased with increasing sevelamer hydrochloride/
carbonate dose. Thus, in sevelamer hydrochloride/
carbonate requirement strata 4800 to 2400,
42400 to 4800, 44800 to 7200, and 47200 mg/d,
mean dose-relativity ratios were 0.79 (95% CI, 0.57
to 1.10), 1.45 (95% CI, 1.20 to 1.75), 2.05 (95% CI,
1.75 to 2.39), and 3.24 (95% CI, 2.89 to 3.66),
respectively, in the pooled cohort (Figure 2). Similar
results were found in the L–S and S–L converters
(Table IV).Tablet Burden
Tablet burden was assessed in the FAP. In the
pooled cohort, tablet burden was 6.6 tablets/d lower
(95% CI, 7.1 to 6.0; Po 0.0001) with lanthanum
carbonate monotherapy than with sevelamer hydro-
chloride/carbonate monotherapy (Table V). Similar
results were found in the L–S and S–L converters.Volume 36 Number 10
Table II. Serum parameters and medication use data according to 30-day period: Unless otherwise indicated, values are given as mean (SD).
Parameter
30-Day Period
90 to 61 60 to 31 30 to 1 1 to 30 31 to 60 61 to 90
S-L converters (n ¼ 128) — — — — — —
Monotherapy SH/C SH/C SH/C LC LC LC
Serum phosphate, mg/dL 6.3 (1.6) 6.2 (1.7) 6.4 (1.8) 5.9 (1.6) 6.0 (1.6) 6.4 (1.9)
Serum calcium, mg/dL 9.2 (0.6) 9.2 (0.6) 9.2 (0.6) 9.2 (0.6) 9.2 (0.6) 9.1 (0.6)
Serum PTH, median
(p25, p75), pg/mL
363.3 (244.3, 518.0) 386.7 (275.7, 601.5)
URR 72.9 (7.5) 72.6 (6.9) 72.8 (7.1) 73.1 (6.4) 72.7 (7.0) 72.8 (6.8)
AVD use, no. (%) 113 (88.3) 110 (85.9) 112 (87.5) 116 (90.6) 119 (93.0) 117 (91.4)
AVD dose, mg/mo 37.4 (90.2) 36.2 (94.3) 36.6 (82.7) 37.0 (80.9) 39.8 (90.3) 38.8 (83.8)
Cinacalcet use, no. (%) 42 (32.8) 44 (34.4) 43 (33.6) 47 (36.7) 47 (36.7) 46 (35.9)
Cinacalcet dose, mg/d 18.2 (33.2) 17.2 (30.9) 16.3 (29.5) 17.4 (29.5) 17.7 (29.7) 17.9 (30.2)
SH/C dose, mg/d 8216.9 (3674.4) 8231.6 (3638.8) 8293.6 (3617.9) — — —
LC dose, mg/d — — — 3362.4 (1282.5) 3389.3 (1308.8) 3442.9 (1395.7)
L-S converters (n ¼ 175) — — — — — —
Monotherapy LC LC LC SH/C SH/C SH/C
Serum phosphate, mg/dL 6.4 (1.8) 6.4 (1.8) 6.5 (1.9) 6.3 (1.8) 6.2 (1.7) 6.4 (1.8)
Serum calcium, mg/dL 9.2 (0.7) 9.1 (0.7) 9.2 (0.6) 9.2 (0.6) 9.2 (0.7) 9.1 (0.7)
Serum PTH, pg/mL median
(p25, p75)
396.8 (271.3, 587.0) 384.5 (265.0, 624.2)
URR 73.1 (7.0) 72.9 (8.1) 73.1 (7.5) 72.7 (7.7) 72.8 (8.0) 72.2 (8.6)
AVD use, no. (%) 151 (86.3) 152 (86.9) 153 (87.4) 154 (88.0) 153 (87.4) 154 (88.0)
AVD dose, mg/mo 37.0 (38.9) 35.9 (36.1) 34.6 (33.8) 34.5 (34.1) 34.1 (34.9) 32.8 (34.7)
Cinacalcet use, no. (%) 80 (45.7) 81 (46.3) 87 (49.7) 89 (50.9) 85 (48.6) 87 (49.7)
Cinacalcet dose, mg/d 27.5 (39.0) 27.4 (38.4) 28.1 (36.7) 28.7 (37.7) 27.5 (37.5) 28.7 (38.2)
SH/C dose, mg/d — — — 8568.7 (3960.8) 8575.6 (3956.3) 8645.2 (3947.0)
LC dose, mg/d 3817.3 (2214.9) 3821.3 (2191.6) 3819.3 (2179.3) — — —
PTH ¼ parathyroid hormone; p25 ¼ 25th percentile; p75 ¼ 75th percentile; URR ¼ urea reduction ratio; AVD ¼ activated vitamin D.
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1436Costs
Phosphate binder costs were assessed in the FAP.
Table VI presents the mean cost difference between
days 30 to 1 (preconversion) and days 61 to 90
(postconversion) for the individual and pooled mono-
therapy cohorts of the FAP. In the S–L cohort, the
conversion from sevelamer hydrochloride/carbonate
to lanthanum carbonate resulted in a mean cost saving
in favor of lanthanum carbonate of $93.66/patient per
month (95% CI cost difference, 185.30 to 2.06;
P ¼ 0.045). In the L–S cohort, the mean cost saving
with lanthanum carbonate was $59.97/patient per
month (95% CI cost difference, 156.60 to 36.66;
P ¼ 0.222). In the pooled cohort, the mean binder
cost/patient per month was $1080.40 for sevelamer
hydrochloride/carbonate compared with $1006.20 for
lanthanum carbonate, corresponding to a mean
binder cost saving for lanthanum carbonate of
$74.20/patient per month (95% CI cost difference,
141.80 to 6.63; P ¼ 0.032). Stratiﬁed analysis
showed that patients with sevelamer hydrochloride/
carbonate requirements 49800 mg/d had mean cost
savings of $504/patient per month (95% CI cost
difference, 662.80 to 345.20; P o 0.0001)
after conversion to lanthanum carbonate (Figure 3).
A sevelamer hydrochloride/carbonate requirement of
47800 mg/d was the inﬂection point at which con-
version to lanthanum carbonate resulted in mean cost
savings. Patients requiring sevelamer hydrochloride/
carbonate 47800 mg/d comprised 50% of the FAP.
To address the question of the general applicability of
the sevelamer hydrochloride/carbonate 47800 mg
inﬂection point, additional ad hoc analyses found
that (as of August 1, 2013) 40% of patients at the
LDO who were taking sevelamer hydrochloride/car-
bonate in tablet form required doses Z8000 mg/d
(see the Supplemental Table in the online version at
http://dx.doi.org/10.1016/j.clinthera.2014.07.012).
DISCUSSION
In this retrospective cohort study, we evaluated the
dose-relativity, tablet burden, and comparative drug
costs of sevelamer hydrochloride/carbonate and lan-
thanum carbonate monotherapies in a large, real-
world dialysis patient population. This analysis rep-
resents the ﬁrst to make use of a bidirectional study
design in which patients converted both from seve-
lamer hydrochloride/carbonate to lanthanum carbon-
ate (S–L converters) and from lanthanum carbonate toVolume 36 Number 10
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Figure 2. Sevelamer hydrochloride/carbonate (SH/C):lanthanum carbonate (LC) dose-relativity ratio accord-
ing to SH/C requirement stratum: pooled cohort. Dose-relativity estimates were assessed in a
subset of patients whose serum phosphate levels for the final preconversion (days 30 to 1) and
postconversion (days 61 to 90) periods fell within a 0.5-mg/mL caliper range. The SH/C:LC dose
ratio distribution was log-transformed and the mean (95% CI) back-transformed to obtain
estimates of the mean in the original scale.
M.S. Keith et al.sevelamer hydrochloride/carbonate (L–S converters).
A key advantage of the bidirectional design was that it
eliminated potential bias associated with the direction
of conversion. The S–L and L–S cohorts comprising
the FAP had broadly similar baseline demographic
characteristics and comorbidity rates. In addition,Table IV. Sevelamer hydrochloride/carbonate (SH/C)
according to dose stratum: SH/C to LC (S–L
SH/C Requirement Stratum (mg/d) No.
S–L converters (n ¼ 72)
4800 to 2400 2
42400 to 4800 15
44800 to 7200 25
47200 30
L–S converters (n ¼ 87)
4800 to 2400 7
42400 to 4800 15
44800 to 7200 18
47200 47
*Dose-relativity estimates were assessed in a subset of patients
(days 30 to 1) and postconversion (days 61 to 90) periods
distribution was log-transformed and the mean (95% CI) back
October 2014there was no evidence of clinically signiﬁcant differ-
ences between the two cohorts in terms of laboratory
assessments or medication use. However, the mean
dialysis duration of the L–S cohort was 1 year longer
than that of the S–L cohort. The slightly higher
phosphate binder doses observed in the L–S cohort:lanthanum carbonate (LC) dose-relativity ratio
converters) and LC to SH/C (L–S converters).*
SH/C:LC Dose-Relativity Ratio: Mean (95% CI)
0.80 (0.41 to 1.55)
1.60 (1.25 to 2.05)
2.09 (1.73 to 2.53)
3.48 (3.02 to 4.23)
0.79 (0.53 to 1.17)
1.31 (0.99 to 1.73)
1.99 (1.54 to 2.56)
3.04 (2.60 to 3.57)
whose serum phosphate levels for the ﬁnal preconversion
fell within a 0.5-mg/mL caliper range. The dose-relativity
-transformed to the original scale.
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Table V. Daily tablet burden and tablet burden differences among converters.* Values are given as mean (SD)
or mean (95% CI).
Conversion SH/C Tablets/Day LC Tablets/Day Tablet Burden Difference,† Tablets/Day
S–L converters
(n ¼ 128)
10.4 (4.5) 3.8 (1.8) 6.6 (7.4 to 5.8)
P o 0.0001‡
L–S converters
(n ¼ 175)
10.8 (5.0) 4.3 (2.5) 6.5 (7.2 to 5.7)
P o 0.0001‡
Pooled converters
(N ¼ 303)
10.6 (4.8) 4.0 (2.2) 6.6 (7.1 to 6.0)
P o 0.0001‡
SH/C ¼ sevelamer hydrochloride/carbonate; LC ¼ lanthanum carbonate; S–L ¼ SH/C to LC; L–S ¼ LC to SH/C.
*Tablet burden was assessed in the full analysis population.
†For S–L converters, the tablet burden difference was calculated as the total daily tablet burden for days 61 to 90 minus the
total daily tablet burden for days 30 to 1. For L–S converters, the tablet burden difference was calculated as the total
daily tablet burden for days 30 to 1 minus the total daily tablet burden for days 61 to 90.
‡The statistical signiﬁcance of the tablet burden difference was assessed by using the paired t test.
Clinical Therapeuticsmay be associated with the longer ESRD dura-
tion of these patients.
The mean sevelamer hydrochloride/carbonate:lan-
thanum carbonate dose-relativity ratio was estimated
as 2.4 for S–L converters, 2.1 for L–S converters, and
2.3 for the pooled cohort. These ﬁgures are com-Table VI. Mean phosphate binder costs and cost differe
(SD) or mean (95% CI).
Conversion SH/C Cost
S–L converters
(n ¼ 128)
1051.50 (465.34) 95
L–S converters
(n ¼ 175)
1101.54 (508.80) 104
Pooled converters
(N ¼ 303)
1080.40 (490.75) 100
SH/C ¼ sevelamer hydrochloride/carbonate; LC ¼ lanthanum c
Phosphate binder costs were based on Red Book (September 20
*Phosphate binder costs were assessed in the full analysis popu
†The cost difference was the LC cost minus the SH/C cost. For S–
daily cost for days 61 to 90 minus the total daily cost for da
calculated as the total daily cost for days 30 to 1 minus th
‡The statistical signiﬁcance of the cost difference was assessed
1438parable to the sevelamer hydrochloride:lanthanum
carbonate dose-relativity ratio estimate of 2.8 recently
reported by Wilson et al.23 This study also cited
estimates of 2.8, based on World Health
Organization–deﬁned daily doses,24 and 2.7, based
on the relative phosphate-binding coefﬁcients of thences among converters.* Values are given as mean
$/Patient/Month
LC Cost Cost Difference†
7.84 (414.08) 93.66 (185.30 to 2.06)
P ¼ 0.045‡
1.57 (573.69) 59.97 (156.60 to 36.66)
P ¼ 0.222‡
6.20 (513.27) 74.20 (141.80 to 6.63)
P ¼ 0.032‡
arbonate; S–L ¼ SH/C to LC; L–S ¼ LC to SH/C.
13) average wholesale prices.20
lation.
L converters, the cost difference was calculated as the total
ys 30 to 1. For L–S converters, the cost difference was
e total daily cost for days 61 to 90.
by using the paired t test.
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Figure 3. Phosphate binder cost difference according to sevelamer hydrochloride/carbonate (SH/C) dose
stratum: pooled converters. Phosphate binder costs were assessed in the full analysis population.
The cost difference was calculated as the lanthanum carbonate (LC) cost minus the SH/C cost. For
the SH/C to LC converters, the cost difference was the total daily cost for days 61 to 90 minus the
total daily cost for days 30 to 1. For LC to SH/C converters, the cost difference was the total
daily cost for days 30 to 1 minus the total daily cost for days 61 to 90. Phosphate binder costs
were based on September 2013 Red Book average wholesale prices.20 The statistical significance of
cost differences was assessed by using the paired t test; *P o 0.0001,†P o 0.05.
M.S. Keith et al.two binders.25 We found that the dose-relativity ratio
rose with increasing sevelamer hydrochloride/
carbonate dose, as also reported by Wilson et al.
In the pooled cohort, the dose-relativity ratio
ranged from 0.8 (sevelamer hydrochloride/carbonate
4800–2400 mg/d) to 3.2 (sevelamer hydrochloride/
carbonate 47200 mg/d).
The mean phosphate binder tablet burden for the
pooled study cohort was signiﬁcantly lower with
lanthanum carbonate monotherapy than with seve-
lamer hydrochloride/carbonate monotherapy, a ﬁnd-
ing that is consistent with those of previous
studies.23,26 The available evidence indicates that a
lower tablet burden is associated with better adher-
ence to phosphate binder medication.27–29
In addition to a reduction in the tablet burden after
conversion to lanthanum carbonate, cost analyses
revealed an overall mean cost saving in the pooled
cohort of $74/patient per month for lanthanum
carbonate monotherapy compared with sevelamer
hydrochloride/carbonate monotherapy. The cost
inﬂection point fell at a sevelamer hydrochloride/
carbonate dose of 47800 mg/d, a dose that wasOctober 2014taken by 50% of patients in the FAP. Additional ad
hoc analyses found that 40% of patients who received
dialysis at the LDO required sevelamer hydrochloride/
carbonate doses Z8000 mg/d. Thus, it is likely that
the cost savings with lanthanum carbonate compared
with sevelamer hydrochloride/carbonate observed in
the present study will be applicable to a broad
segment of patients with ESRD. These ﬁndings have
potential implications for nephrologists, particularly
in light of emerging changes to the reimbursement
system for ESRD services.21,22 The results of the cost
analyses presented here are consistent with previous
economic evaluations demonstrating the cost-effec-
tiveness of lanthanum carbonate as second-line treatment
for hyperphosphatemia from Australian, Canadian,
Japanese, UK, and US payer perspectives.30–34
Several limitations of the study should be noted.
These analyses were limited to patients enrolled in the
LDO’s pharmacy management program. The fact that
not all patients in the LDO were enrolled in this
program raises the question of how representative the
analysis population is of patients outside the program,
and of patients with ESRD in general. In addition,1439
Clinical Therapeuticsthese analyses were limited to patients receiving
phosphate binder monotherapy, who may not be
representative of broad-based clinical practice in the
management of hyperphosphatemia in patients with
ESRD. The 0.5-mg/dL serum phosphate caliper range
in the preconversion and postconversion periods was
a necessary element of the study design that enabled
us to estimate the dose-relativity ratio by using doses
that achieved similar phosphate control. However, the
study may have been strengthened by sensitivity
analyses that varied the caliper range or that focused
on patients with serum phosphate levels within the US
National Kidney Foundation Kidney Disease Out-
comes Quality Initiative target range of r5.5 mg/
dL.6 A weakness of retrospective studies is that
patient-level data are not collected for research pur-
poses, and, thus, there tends to be a high level of
missing data.35 For example, patient adherence data
were not available in the present study.CONCLUSIONS
In this retrospective cohort study of a large, real-world
dialysis patient population, the mean sevelamer
hydrochloride/carbonate:lanthanum carbonate dose-
relativity ratio was 2.27 (95% CI, 2.04 to 2.52). This
ﬁnding translated to an overall mean tablet burden for
lanthanum carbonate monotherapy that was 6.6
tablets/d lower than that for sevelamer hydro-
chloride/carbonate monotherapy (95% CI, 7.1 to
6.0; P o 0.0001). The overall mean binder cost/
patient per month was $1080.40 for sevelamer
hydrochloride/carbonate compared with $1006.20
for lanthanum carbonate, corresponding to a mean
binder cost saving for LC of $74.20/patient per month
(95% CI, 141.80 to 6.63; P ¼ 0.032). Sevelamer
hydrochloride/carbonate 47800 mg/d was the inﬂec-
tion point at which conversion to lanthanum carbo-
nate resulted in mean cost savings. Patients requiring
sevelamer hydrochloride/carbonate47800 mg/d com-
prised 50% of the analysis population.
Converting patients with ESRD from sevelamer
hydrochloride to lanthanum carbonate offers potential
drug cost savings and a reduction in the daily tablet
burden, without compromising the effective manage-
ment of serum phosphate levels. These ﬁndings have
potential implications for nephrologists considering
the appropriate phosphate binder to use in the
management of patients with hyperphosphatemia,1440particularly in light of emerging changes to the
reimbursement system for ESRD services.
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Supplemental Table. Distribution of daily sevelamer
hydrochloride/carbonate dose
among tablet-only users atten-
ding the large dialysis organi-
zation for treatment.
Percentile Dose (mg/d)
10 2400
20 4000
30 4800
40 6400
50 7200
60 8000
70 9600
80 10,400
90 12,800
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